Kopsiloscine E



Compound IDCDAMM00622
Common nameKopsiloscine E
IUPAC namedimethyl 15,17,18-trihydroxy-6-methoxy-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-2,18-dicarboxylate
Molecular formulaC24H30N2O8

Experimental data

Retention time12.75
Adduct[M+K]+
Actual mz513.157
Theoretical mz513.163
Error12
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.7482

Identifiers and class information

Inchi keyFELVAZDUIFIGTH-OOSLBVOUNA-N
SmilesO=C(OC)N1C2=CC=C(OC)C=C2C34CCN5CCC(O)C6(CCC13C(O)(C(=O)OC)C6O)C54
SuperclassAlkaloids and derivatives
ClassAspidofractine alkaloids

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)5
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)474.51
Computed dipole moment(dipole)7.541
Total solvent accessible surface area (SASA)656.906
Hydrophobic component of SASA (FOSA)461.488
Hydrophilic component of SASA (FISA)124.942
Pie component of the SASA (PISA)70.477
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1299.18
Number of hydrogen bond donors (donorHB)2
Number of hydrogen bond acceptors (accptHB)10.4
Free energy of solvation of dipole (dip^2/V)0.0437753
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0223895
Globularity descriptor (glob)0.876545
Predicted polarizability in cubic angstroms (QPpolrz)43.302
Predicted hexadecane/gas partition coefficient (QPlogPC16)12.103
Predicted octanol/gas partition coefficient (QPlogPoct)23.38
Predicted water/gas partition coefficient (QPlogPw)14.699
Predicted octanol/water partition coefficient (QPlogPo/w)1.79
Predicted aqueous solubility (QPlogS)-2.621
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.043
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.592
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)161.427
Predicted brain/blood partition coefficient (QPlogBB)-0.423
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)76.233
Predicted skin permeability, log Kp (QPlogKp)-5.156
PM3 calculated ionization potential (IP(ev))8.646
PM3 calculated electron affinity (EA(eV))0.16
Number of likely metabolic reactions (#metab)4
Prediction of binding to human serum albumin (QPlogKhsa)-0.003
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)76.947
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)125.157
Number of nitrogen and oxygen atoms (#NandO)10
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction
P00533EGFREpidermal growth factor receptor erbB1T59328SwissTargetPrediction
O00754MAN2B1Lysosomal alpha-mannosidaseT63156SwissTargetPrediction
Q16739UGCGCeramide glucosyltransferaseT14908SwissTargetPrediction
P00491PNPPurine nucleoside phosphorylaseT78198SwissTargetPrediction
Q9H3N8HRH4Histamine H4 receptorT26500SwissTargetPrediction
P22894MMP8Matrix metalloproteinase 8T08856SwissTargetPrediction
P21728DRD1Dopamine D1 receptorT22118SwissTargetPrediction
P07550ADRB2Adrenergic receptor betaT52522SwissTargetPrediction
P13945ADRB3Beta-3 adrenergic receptorT51408SwissTargetPrediction
P25100ADRA1DAlpha-1d adrenergic receptorT53381SwissTargetPrediction
P11388TOP2ADNA topoisomerase II alphaT17048SwissTargetPrediction
P30307CDC25CDual specificity phosphatase Cdc25CT40569SwissTargetPrediction
Q13126MTAPS-methyl-5-thioadenosine phosphorylaseT40787SwissTargetPrediction
P48048KCNJ1ATP-sensitive inward rectifier potassium channel 1T78710SwissTargetPrediction
P17707AMD1S-adenosylmethionine decarboxylase 1T55922SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
T59328DI0030Angina pectoris[ICD-11: BA40]P00533EGFR
T59328DI0062Breast cancer[ICD-11: 2C60-2C6Y]P00533EGFR
T59328DI0095Colorectal cancer[ICD-11: 2B91]P00533EGFR
T59328DI0121Diabetic foot ulcer[ICD-11: BD54]P00533EGFR
T59328DI0220Ischemia[ICD-11: 8B10-8B11]P00533EGFR
T59328DI0238Lung cancer[ICD-11: 2C25]P00533EGFR
T59328DI0303Non-small-cell lung cancer[ICD-11: 2C25]P00533EGFR
T59328DI0361Renal cell carcinoma[ICD-11: 2C90]P00533EGFR
T59328DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P00533EGFR
T59328DI0420Unspecific body region injury[ICD-11: ND56]P00533EGFR
T63156DI0242Lysosomal disease[ICD-11: 5C56]O00754MAN2B1
T14908DI0242Lysosomal disease[ICD-11: 5C56]Q16739UGCG
T14908DI0257Metabolic disorder[ICD-11: 5C50-5D2Z]Q16739UGCG
T78198DI0120Diabetes mellitus[ICD-11: 5A10]P00491PNP
T78198DI0167Gout[ICD-11: FA25]P00491PNP
T78198DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P00491PNP
T78198DI0283Mycosis fungoides[ICD-11: 2B01]P00491PNP
T78198DI0351Psoriasis[ICD-11: EA90]P00491PNP
T26500DI0037Asthma[ICD-11: CA23]Q9H3N8HRH4
T26500DI0039Atopic eczema[ICD-11: EA80]Q9H3N8HRH4
T26500DI0351Psoriasis[ICD-11: EA90]Q9H3N8HRH4
T26500DI0366Rheumatoid arthritis[ICD-11: FA20]Q9H3N8HRH4
T26500DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q9H3N8HRH4
T08856DI0366Rheumatoid arthritis[ICD-11: FA20]P22894MMP8
T22118DI0003Abortion[ICD-11: JA00]P21728DRD1
T22118DI0022Allergic/hypersensitivity disorder[ICD-11: 4A80-4A8Z]P21728DRD1
T22118DI0190Hypertension[ICD-11: BA00-BA04]P21728DRD1
T22118DI0331Parkinsonism[ICD-11: 8A00]P21728DRD1
T52522DI0037Asthma[ICD-11: CA23]P07550ADRB2
T52522DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P07550ADRB2
T52522DI0097Conduction disorder[ICD-11: BC63]P07550ADRB2
T52522DI0344Preterm labour/delivery[ICD-11: JB00]P07550ADRB2
T52522DI0387Sleep-related breathing disorder[ICD-11: 7A4Z]P07550ADRB2
T51408DI0030Angina pectoris[ICD-11: BA40]P13945ADRB3
T51408DI0037Asthma[ICD-11: CA23]P13945ADRB3
T51408DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P13945ADRB3
T51408DI0129Dystonic disorder[ICD-11: 8A02]P13945ADRB3
T51408DI0154Functional bladder disorder[ICD-11: GC50]P13945ADRB3
T51408DI0190Hypertension[ICD-11: BA00-BA04]P13945ADRB3
T51408DI0331Parkinsonism[ICD-11: 8A00]P13945ADRB3
T53381DI0166Glaucoma[ICD-11: 9C61]P25100ADRA1D
T53381DI0175Heart failure[ICD-11: BD10-BD1Z]P25100ADRA1D
T53381DI0190Hypertension[ICD-11: BA00-BA04]P25100ADRA1D
T53381DI0348Prostate hyperplasia[ICD-11: GA90]P25100ADRA1D
T53381DI0378Sexual dysfunction[ICD-11: HA00-HA01]P25100ADRA1D
T53381DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P25100ADRA1D
T17048DI0012Acute myeloid leukaemia[ICD-11: 2A60]P11388TOP2A
T17048DI0225Kaposi sarcoma[ICD-11: 2B57]P11388TOP2A
T17048DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P11388TOP2A
T40787DI0275Multiple sclerosis[ICD-11: 8A40]Q13126MTAP
T55922DI0004Acidosis[ICD-11: 5C73]P17707AMD1

Copyright © 2025